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 Ab stract
Despite the envisioned breakthrough prophesied for 
the end of the past century in healing brain injured pa-
tients, both clinicians and basic scientists are still strug-
gling with this burden. In the past decades, intensive 
research has brought forward a plethora of different 
targets which – in part – have already been integrated 
in clinical routine directed at detailed monitoring, ther-
apeutic interventions, and prevention of secondary de-
terioration. While intracellular targets remain obscure 
alterations on a larger scale as e.g., measured intracra-
nial pressure (ICP), calculated cerebral perfusion pres-
sure (CPP), and various imaging techniques are funda-
mental components of our present clinical 
understanding. At bedside, comprehension of patho-
physiological loops and circuits of a given value (e.g., 
ICP) depends on individual knowledge, interpretation, 
and availability of additional diagnostic steps. As stated 
in the guidelines brought forward by the American As-
sociation of Neurological Surgeons and evaluated in 
various reports by the Cochrane Library we are still lack-
ing prospective, randomized trials for the majority of 
the proposed diagnostic and therapeutic interventions. 
In this context, a recent meta-analysis even questioned 
the importance of ICP monitoring as we are lacking da-
ta from randomized controlled trials clarifying the role 
of ICP monitoring. The present review is to give an over-
view of various diagnostic and therapeutic possibilities 
based on reports published in the past 5 years to 
strengthen current approaches and nourish future 
well-designed investigations how to avoid and treat in-
tracranial hypertension.
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Introduction
The most feared complication following severe trau-
matic brain injury (TBI) is an increase in intracranial 
pressure (ICP) which may also become therapy-refrac-
tory making ensuing death inevitable. Elevated ICP as 
measured continuously is a number which requires thor-
ough and differentiated analysis of various possible rea-
sons (Figure 1). In this context, the time point of intra-
cranial hypertension is crucial: during the early phase 
(minutes/hours to initial 2–3 days), new onset or signifi-
cant progression of hemorrhages and edema are the 
most common reasons [1]. Developing intracranial hy-
pertension at later time points which is not observed 
under standard experimental conditions can be caused 
by progressing perifocal and generalized edema forma-
tion and disturbed vascular responsiveness. Overall, 
compression and edema form a vicious circle with vari-
ous potential therapeutic targets (Figure 2). In this con-
text, the heterogeneity of TBI with its different lesions 
might require lesion-dependent interventions. The easi-
est treatment step is the surgical removal of space-occu-
pying lesions compressing the brain (subdural and epi-
dural hematoma [SDH, EDH]) providing their speed of 
development has not surpassed the time point of sal-
vageable iatrogenic intervention. More complicated to 
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treat and correct are different chang-
es developing in parallel and sequen-
tially which can induce or aggravate 
underlying damage over time. De-
spite the intense research and the 
promising results obtained by spe-
cifically modulating identified cellu-
lar targets in “non-intensive care 
unit (ICU) rodents” [2], the equally 
successful implementation of these 
laboratory results in ICU patients 
with severe TBI has failed. Just re-
cently, the Dexanabinol trial which 
had been envisioned to provide an 
effective therapy by inhibiting cellu-
lar damage mediated by reactive 
oxygen species, glutamate and tu-
mor necrosis factor was announced 
a failure. Consequently, we are left 
with our basic treatment possibili-
ties.
In this review, the authors have 
tried to address the old issues and 
questions on how to treat intracra-
nial hypertension, focusing on find-
ings published in the past 5 years.
Identification of 
Secondary Injury and 
Deterioration
Both, clinical and experimental re-
search strongly support the percep-
tion that reliable and easy-to-per-
form monitoring techniques and 
methods are indispensable to un-
mask further deterioration and to 
also initiate and guide specific ther-
apeutic and pharmacological inter-
ventions. For this, measuring chang-
es in ICP is the most efficient basic 
monitoring method to reveal patho-
logic alterations within the intracra-
nial compartment which is comple-
mented by additional monitoring approaches. ICP 
values as such are nonspecific as they cannot differenti-
ate the actual cause for the observed increase in ICP 
(Figure 1). Nevertheless, ICP monitoring is crucial in 
prompting diagnostic steps and guiding therapeutic in-
terventions.
Overall, secondary injury is characterized by its dy-
namic development initiated by the primary injury. In 
this context, speed, duration, and extent of injury pro-
gression are variable in time and location and appear to 
be different for structural and functional damage. Pro-
gression and new onset of structural lesions occur pre-
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Figure 1. Schematic drawing showing possible pathophysiological circuits which contribute to 
intracranial hypertension following severe TBI which, in turn, can activate or aggravate under-
lying pathologic changes. Corrective interventions are limited.
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Figure 2. The intracranial volume is influenced by different compartimentalized components 
which, however, influence each other. To a certain extent these components are individual 
therapeutic targets. However, it is important to understand that aggressive treatment of one 
component might induce adverse and deleterious effects in a different part owing to the tight 
functional dependencies.
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dominantly within the first 24–72 h. Edema formation 
develops in parallel but persists longer than hemorrhag-
es which show signs of resolution within 5 days. Conse-
quently, the initial hours to days are the most crucial 
phase requiring intensive monitoring to identify second-
ary deterioration. Nevertheless, the subsequent days to 
weeks are overshadowed by potential secondary insults 
related to focal or diffuse ischemia, persistingly open 
blood-brain barrier, the inflammatory response, infec-
tions, and other organ complications which have been 
shown to influence morbidity and mortality [3].
Since revelation of functional deterioration is the 
key in improving our current therapy, the following sec-
tion summarizes the different monitoring techniques 
which are used to assess development, extent, and re-
gression of various causes of elevated ICP.
Brain Imaging
While the readily available CT (computed tomography) 
analysis is an integral and widely employed part in eval-
uating presence, severity, and development of structural 
intracranial pathologies, it does not reflect new onset or 
progression of functional deterioration. Other imaging 
techniques known to disguise functional changes (PET 
[positron emission tomography], SPECT [single-photon 
emission computed tomography], H-MRS [proton mag-
netic resonance spectroscopy], MRI [magnetic reso-
nance imaging]) are not readily available, difficult to 
conduct in cardiopulmonary and hemodynamically un-
stable patients, can only be performed discontinuously, 
are still academic in nature, and have not been integrat-
ed in the actual clinical management. Assessment of 
functional disturbances is crucial to induce and adapt 
therapeutic interventions. In the classic ICU setting 
with sedated and mechanically ventilated patients 
“functional disturbance” refers to changes on the cellu-
lar level which involves not only neurons but also astro-
cytes and endothelial cells. In this context, it is impor-
tant to comprehend that actual cell-based alterations 
are highly dynamic processes which influence each oth-
er in a heterogeneous spatial and temporal manner.
Present conclusions. In daily routine CT analysis is 
the mainstay within the diagnostic and therapeutic deci-
sion-making. During the acute phase only MRI studies 
with their logistic and patient-dependent difficulties are 
justified to determine brain stem lesion which otherwise 
are not visible on CT scans. Assessing functional altera-
tions by MRI and PET requires an active and coopera-
tive patient and, thus, is of inferior assistance in coma-
tose and sedated patients.
Intracranial Pressure (ICP) and Compliance
The hallmark of posttraumatic structural and functional 
disturbance is an elevation in ICP due to increased in-
tracranial volume related to expanding hemorrhages 
(EDH, SDH, contusions) and/or accumulation of water 
within the extracellular and intracellular compartment, 
known as vasogenic and cytotoxic edema. Furthermore, 
insufficient as well as sustained cerebral perfusion (hy-
peremia) due to ischemia and increased intracranial 
blood volume, respectively, can induce intracranial hy-
pertension [4, 5]. For this, introduction of ICP monitor-
ing devices within the subdural space, brain parenchyma 
and ventricular system are integrated in the routine 
treatment of these patients. As evaluated within the 
guidelines brought forward by the American Associa-
tion of Neurological Surgeons (AANS; www2.brain-
trauma.org/guidelines/downloads/btf_guidelines_man-
agement.pdf) subarachnoid, subdural, and epidural 
monitors are less accurate compared to parenchymal 
and ventricular ICP probes. In this context, it is impor-
tant to comprehend that the suggested ICP threshold of 
15 mmHg is based on supratentorial measurements, as 
patients can also herniate with normal values, if the ex-
panding lesion is located in close proximity of the brain 
stem. In general, ICP values > 15 mmHg reflect underly-
ing pathology and any increase exceeding 25 mmHg 
should prompt further diagnostic evaluation (see AANS 
guidelines).
Determination of intracranial compliance as a mea-
sure of increased stiffness of the brain by infusing fixed 
amounts of fluid in the ventricular system is thought to 
unmask a pathologic pressure-volume relationship and 
to also predict forthcoming hypertension when small in-
creases in volume induce a larger than normal increase 
in pressure under conditions of exploited compensatory 
mechanisms as seen in cases of space-occupying lesions. 
As a function of elevated ICP the tolerable amount of 
injectable volume into the ventricular system decreases 
significantly, as ICP exceeds 20 mmHg, irrespective of 
age [6]. However, given a low incidence of episodes 
identified to adequately predict pathologically elevated 
ICP, i.e., 16% of 225 episodes determined in ten patients 
suffering from severe TBI, this technique requires fur-
ther modification before it can be introduced in the 
clinical routine as an early warning system for ensuing 
deterioration [6].
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Present conclusions. Measuring ICP is the crucial 
and central monitoring parameter for any physician 
treating patients with TBI. Changes in ICP need to 
prompt more in-depth diagnosis to determine the cause 
for intracranial hypertension, thereby allowing more 
specific treatment, and to prevent uncontrollable de-
compensation. Assessing ICP automatically provides 
information about global cerebral perfusion, as the ce-
rebral perfusion pressure (CPP) results from ICP and 
mean arterial blood pressure (MABP). Translation of 
bedside analysis of disturbed intracranial compliance to 
daily routine has not been completed due to technical 
limitations.
Electrophysiological Investigations (EEG, EPs)
Disturbances in neuronal activity and axonal conduc-
tance can be assessed by electroencephalography (EEG) 
and evoked potentials (EPs) which can determine the 
site of functional impairment and even allow prognostic 
statements [7]. Cortical responsiveness to exteroceptive 
tactile, acoustic, and noxious stimuli requires intact 
transmission from the periphery to central areas (sen-
sory stimulation) with adequate processing in the gray 
matter. On a cellular level, excitatory and inhibitory in-
puts require viable and metabolically active neurons 
and astrocytes to generate and modulate electrogenic 
potentials arising from cortical and subcortical struc-
tures. Any disturbance due to structural lesions within 
the white or gray matter of brain and spine or functional 
impairment related to hypothermia and administered 
sedative drugs can hamper the reliability of these inves-
tigations. Nevertheless, these techniques allow insight 
into pathologic alterations which in conjunction with 
metabolic analysis might unmask severity of injury and 
pharmacological reversibility as suggested by the find-
ings of Vespa et al. who were able to reveal nonconvul-
sive status epilepticus which otherwise had gone unde-
tected [8]. Consequently, specialists recommend 
continuous EEG monitoring during the initial 48 h [9].
Present conclusions. EEG analysis remains a con-
troversial area due to its physiological, pathophysiologi-
cal and technical complexity, since we can neither deter-
mine the actual anatomic depth at which changes are 
induced nor assess the extent of neuronal and glial im-
balance. More refined and simplified approaches as e.g., 
the BIS (bispectral index) EEG might reveal neuronal 
stability or instability continuously at bedside, possibly 
helping to disguise neuronal from glial activity, when-
ever surrogate markers as e.g., decreased jugular venous 
oxygen saturation (SjvO2) occur in face of decreased 
EEG (neuronal) activity. EPs are helpful in assessing 
brain stem lesions, thereby aiding the complex decision 
process.
Microdialysis
Recent introduction of microdialysis in the clinical rou-
tine has opened the possibility to unmask otherwise oc-
cult pathologic metabolic alterations based on routine 
analysis of glutamate, glucose, lactate, pyruvate, and 
glycerol [10], and calculated indices. In addition, phar-
macokinetic studies can be performed [11]. A large 
number of reports have convincingly demonstrated its 
applicability and usefulness in assessing cellular impair-
ment following TBI, providing certain limitations are 
considered. The low spatial and temporal resolution 
dictated by the position and speed of dialysis, respec-
tively [12], do not allow to transfer these local altera-
tions to distant areas and might not be able to reveal 
ensuing changes early enough to allow preemptive in-
terventions. In addition, recovery rate is not routinely 
determined under in vivo conditions by injecting a met-
abolically inert substance via a second microdialysis 
catheter inserted in close proximity [13]. Furthermore, 
we cannot correct for concentration or dilution effects 
due to edema-related shrinkage or expansion of the ex-
tracellular space and we are not able to exclude diffu-
sion handicap caused by activated glia surrounding the 
catheter over time.
Present conclusions. Cerebral microdialysis disguis-
es local pathologic processes as well as pharmacody-
namic effects. Whether the latency of these changes 
might be overcome by a higher sampling rate (1- to 
5-min intervals vs. routine 30-min intervals) which in-
creases the logistical and personal workload remains 
unclear. In this context, a sophisticated automated arti-
fact recognition tool becomes indispensable. The asso-
ciated costs limit its general integration.
Cerebrospinal Fluid (CSF) Analysis
In patients with noncompressed lateral ventricles, ven-
tricular catheters are inserted to lower ICP by draining 
CSF. This approach can also be used to determine meta-
bolic and immunologic changes [14] in CSF to unmask 
underlying pathologic changes. This technique, howev-
er, is compromised by certain methodological pitfalls. 
For one, drained CSF reflects global changes and mea-
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sured solutes are strongly influenced by intracisternal 
blood, the bulk flow toward the ventricular system 
washing these substances out of the brain, and the speed 
and amount of produced and resorbed CSF which might 
change over time and is not quantified under clinical 
conditions. Furthermore, there is no clear consensus 
whether single or repetitive measurements are required 
or if CSF needs to be collected continuously. The fact 
that ventricular catheters cannot be inserted in patients 
with narrow or compressed lateral ventricles or CSF 
cannot be drained due to progressive edema-related 
compression of the ventricular system implies that only 
patients with brain injuries of a presumably lesser ex-
tent or a more complicated secondary development are 
investigated. This, in turn, does not allow to extrapolate 
the determined changes to all patients. Nevertheless, 
this technique allows to assess the impact of underlying 
type of brain lesions and can also be used for pharma-
codynamic and pharmacokinetic studies. In this con-
text, highest glutamate and hypoxanthine concentra-
tions were determined in patients with contusions and 
mixed lesions compared to control patients (lumbar 
CSF) and patients with isolated SDH or EDH (Figure 
3). Inducing a burst suppression pattern by the admin-
istration of thiopental resulted in a significant decrease 
in CSF glutamate, lactate and hypoxanthine concen-
trations [15].
Present conclusions. CSF analysis remains a simple 
monitoring approach which, however, is limited to pa-
tients with less or more severe injuries, depending on 
the size of the ventricular system. The fear for ventricu-
lostomy-related infections might restrain this ap-
proach.
Jugular Bulb Catheter
Retrograde insertion of a special catheter in the internal 
jugular vein allows to continuously determine changes 
in SjvO2 [16] and discontinuously measure arterio-jugu-
lar venous differences of humoral and cellular compo-
nents leaving or entering the brain [17–20]. This moni-
toring approach reflects global alterations and is 
routinely used to guide and control hyperventilation to 
reduce elevated ICP. This allows to detemine hyperven-
tilation-induced vasoconstriction and prevent injury-ag-
gravating ischemia [21]. As any attempt to study meta-
bolic and thus functional alterations, concomitant drug 
administration needs to be considered, as pharmacody-
namic influences may supervene. In this context, we 
have observed a significant reduction in lactate pro-
duction reflected by the lower frequency of negative 
arterio-jugular venous lactate differences in patients 
subjected to high-dose barbiturate coma compared to 
patients receiving benzodiazepines and opioids (Fig-
ure 4).
Different SjvO2 values were identified to have a 
therapy-guiding potential: while SjvO2 values < 50% re-
flect ischemia, levels between 50 and 65% could reveal 
impending ischemia, and SjvO2 between 65 and 75% are 
considered normal; levels > 76% reflect hyperemia or 
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Figure 3. Influence of different traumatic brain lesions on CSF gluta-
mate and hypoxanthine concentrations, reflecting underlying excito-
toxicity and energetic impairment. Highest levels were observed in 
patients presenting with contusions (*p < 0.05 vs. controls).
Figure 4. In patients with therapy-refractory intracranial hyperten-
sion, administration of high-dose thiopental significantly reduced the 
frequency of metabolic compromising events reflected by a decreased 
number of pathologically elevated jugular venous lactate (negative 
arterio-jugular venous difference) compared to patients treated with 
fentanyl and midazolam (*p < 0.001).
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vast depression of metabolism characteristic of severe 
injuries. Most frequent causes for pathologically de-
creased SjvO2 values are hyperventilation, hypovole-
mia, and anemia which can be prevented or corrected, 
thereby reducing incidence of intracranial hypertension 
and improving outcome [1].
Present conclusions. Retrograde cannulation of the 
internal jugular bulb to monitor cerebral alterations is 
technically easy but is limited by the frequency of analy-
sis and the declining data quality within several days fol-
lowing insertion of the fiber-optic catheter. Measuring 
arterio-jugular venous differences might complement 
multimodal monitoring especially in regard to systemic 
influences related to diseases known to develop over 
time in critically ill patients (e.g., organ dysfunction, in-
fections, sepsis, etc.). With this approach more patients 
could be monitored especially if penetrating probes 
(microdialysis, tissue probes) cannot be introduced.
Brain Tissue Oxygenation
Following TBI, the injured brain is in a state of distress 
characterized by sustained vulnerability owing, among 
other reasons, to its limited energetic reserves in face 
of sustained and dysregulated excitation. Consequent-
ly, the brain requires sufficient oxygen to prevent ad-
ditional cell damage from impaired oxidative metabo-
lism necessary to meet activation-induced increases in 
energy demands. Changes in tissue pO2 (ptiO2) reli-
ably reveal evolving tissue perturbation. Detrimental 
ptiO2 threshold below which ischemic damage devel-
ops and which is associated with pathologic neuro-
chemical alterations [22] and a worse outcome is 8–10 
mmHg [23, 24]. Changes in ptiO2 can also serve to dis-
criminate anaerobic from nonoxidative metabolism, as 
an increase in extracellular lactate can also be caused 
by sustained activity and adapted lactate utilization in 
face of adequate perfusion and supply with oxygen and 
nutrients. Similar to the SjvO2, local ptiO2 changes can 
be used to assess limits of hyperventilation and thus 
guide this therapeutic intervention [25]. This technique 
with its monitoring confined to a small area of interest 
at the cortical-subcortical junction within the frontal 
cortex of the uninjured or lesser injured hemisphere 
faces similar methodological limitations as the bio-
chemical monitoring via microdialysis. This cannot be 
overcome by its high temporal resolution with a sam-
pling rate of 1–10 recordings/min.
Present conclusions. As seen with microdialysis, 
ptiO2 recordings require insertion of penetrating probes 
which might not be feasible in patients with bifrontal 
lesions. Due to the high frequency of data recording a 
sophisticated artifact recognition software is indispens-
able to guarantee reliable interpretation of the collected 
data. The long “calibration” of up to 6 h limits its useful-
ness during the early period following probe place-
ment.
Cerebral Perfusion
Ever since its initial description by Graham et al. in 
1978 [26] reporting ischemic damage in 91% of pa-
tients succumbing to their nonmissile head injuries, 
diagnosis, avoidance, and treatment of impaired per-
fusion following severe TBI have prompted a multi-
tude of clinical and experimental studies. The easiest 
but also most crude assessment of cerebral perfusion 
is to calculate the difference between MABP and 
ICP. This number, however, does not reflect regional 
alterations which are known to be extremely hetero-
geneous. Assessing cerebral perfusion can be per-
formed invasively and noninvasively. As recently and 
convincingly shown by Vajkoczy et al. [27], insertion 
of a special thermodilution probe allows to continu-
ously and reliably determine changes in cerebral per-
fusion as evaluated by simultaneous stable xenon-
enhanced computerized tomography scanning 
(sXe-rCBF) which contrary to the laser Doppler 
methods reveals absolute flow values [ml/100 g/min]. 
In a small series of patients, Jaeger et al. [28] could 
show that this technique allows to detect impaired 
perfusion judged by the changes in ptiO2. Unfortu-
nately, as other catheters used to aid neurointensive 
care, this probe “only” reveals local alterations. As-
sessing global changes in cerebral blood flow (CBF) 
at bedside using the transcranial thermo-dye-dilution 
technique, however, has yielded uncertain results 
compared to xenon-CT measurements [29].
Noninvasive bedside transcranial Doppler evalua-
tion does not only reveal changes in blood flow velocity 
of the extra- and intracranial vessels but may also reflect 
microcirculatory impairment following TBI, as the low 
flow velocity which was reported to be most prominent 
ipsilateral to a focal pathology is associated with de-
creased ptiO2, especially within the first days following 
injury [30]. This technique is performed discontinuously 
but with a higher frequency compared to imaging stud-
ies.
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Imaging studies with their high spatial resolution 
are limited by the fact that these discontinuously per-
formed and logistically challenging studies can only pro-
vide “snapshot” views. Perfusion CT [31], SPECT [32], 
PET [21], perfusion-weighted MRI [33], and xenon-CT 
[29] can reveal localization and extent of underlying im-
paired perfusion and ischemia and even unmask basal 
ganglia hypoperfusion.
Apart from identifying ischemia, assessing changes 
in perfusion is essential to determine if increased CBF 
exceeding the metabolic demand reflects hyperemia. 
This could result from sustained brain damage or an in-
creased pressure load due to impaired autoregulation 
which could be reduced by lowering CPP.
Present conclusions. Although decreased as well as 
increased cerebral perfusion are the most crucial patho-
physiological changes accounting for secondary dam-
age, routine surveillance of disturbed perfusion is pre-
dominantly based on surrogate markers (ptiO2, SjvO2, 
metabolic changes). More widespread application of 
bedside continuous approaches combining regional and 
global perfusion is important to improve both under-
standing and therapeutic guidance. This will automati-
cally facilitate interpretation of other monitoring pa-
rameters, and thereby either initiate or stop therapeutic 
interventions.
Proteomics
Due to its recent commercial availability, analysis of 
various proteins determined in microdialysis or CSF 
samples can be used to investigate changes of extracel-
lular and even intracellular proteins following their re-
lease or liberation. This approach might allow to iden-
tify proteins which might be useful predictors for disease 
characteristics following TBI as seen after stroke [34].
Present conclusions. More data is needed before a 
meaningful conclusion may be drawn.
Cerebral Monitoring: Is it Local Versus Global 
or a Combination of Both?
Successful development and feasible transfer from 
bench to bedside have facilitated the integration of vari-
ous monitoring techniques in the daily routine support 
and care of patients with severe TBI. Nevertheless, as 
with any – especially novel – “experimental” diagnostic 
approach certain limitations inherent to the applied 
techniques and methods can make the clinical decision 
process more difficult, as differentiated interpretation 
of collected data might not reveal pathologic alterations 
at the time point of evaluation but may only become 
obvious following post hoc analysis. Insertion of special 
catheters despite their small diameters (ICP probe: 1 
mm; ptiO2: 0.8 mm; microdialysis: 0.8 mm; thermodilu-
tion probe: 1 mm) carries a risk of additional damage, 
mainly hemorrhage especially in preinjured regions. 
Thus, these catheters should only be inserted within the 
frontal cortex to avoid any damage to the primary and 
secondary sensory and motor fields located more poste-
rior.
While these catheters are generally assumed to only 
reflect local changes confined to a small volume sur-
rounding these probes – used to argue against their use-
fulness –, this must be challenged by the fact that this 
assumption might only hold true at low ICP levels and 
maybe also in craniectomized patients. Under experi-
mental [35] and clinical [36] conditions the rigid skull 
will translate increased pressure caused by a focal or 
hemispheric lesion to the contralateral hemisphere and 
also to other regions within the ipsilateral hemisphere 
over time as the existing pathology extends. Conse-
quently, monitoring the contralateral or lesser injured 
hemisphere will reveal serious and relevant alterations 
reflecting severity and extent of underlying disturbance. 
This, in turn, implies that whenever pathologic altera-
tions occur in the contralateral hemisphere, functional 
integrity of the entire brain needs to be considered at 
stake. The initial conception that metabolic abnormali-
ties are restricted to superficial regions has been recent-
ly questioned, as a significant reduction in metabolic 
oxygen rate was also observed in subcortical white mat-
ter remote from focal hemorrhagic lesions, suggesting 
more diffuse injuries [37]. However, the studied patients 
were heterogeneous in terms of injury severity, consid-
ered time points, and administered drugs.
The strong need to closely monitor patients with se-
vere TBI and to start as early as possible to avoid miss-
ing preventable insults which increase morbidity and 
mortality has become self-understood. This is strength-
ened by retrospective reports showing a significant 
reduction in mortality, increase in functional out -
come, shortened hospitalization, and reduction in costs 
[38–40]. Nevertheless, critics still question the need for 
intensified monitoring, as the efficacy of ICP and multi-
modal monitoring has never been studied in a 
prospective, randomized clinical trial [41]. Overall, 
there is a growing body of evidence showing that these 
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monitoring techniques and methods 
integrated in the neurointensive care 
setting to date can detect deteriora-
tion, guide therapeutic and pharma-
cological interventions, and thereby 
contribute to the improvement of 
these patients. Thus, designing a 
randomized trial assigning patients 
to a nonmonitoring arm would be 
unethical and therefore inapplica-
ble. However, the extent and fre-
quency of monitoring could be sub-
jected to a randomized trial. 
Furthermore, the length of monitor-
ing required to guarantee a more fa-
vorable outcome still remains under 
debate. While some centers discon-
tinue monitoring and sedation after 
a few days, other centers maintain 
monitoring and sedation until ICP 
remains stable without exceeding 20 
mmHg. Based on our own experi-
ence, ICP can steadily increase dur-
ing the first week, surpass 15 mmHg during the second 
week and approach 20 mmHg by the end of the second 
week (Figure 5).
Present conclusions. Further technical development 
and more widespread application of various monitoring 
techniques in primary and tertiary hospitals will gener-
ate more data and substantiate our knowledge which, in 
turn, will improve the overall treatment. It remains to 
be determined which parameters must be monitored 
and which are facultative to disguise evolving deteriora-
tion and improvement. In general, various parameters 
need to be combined to guarantee a holistic surveillance 
of local and systemic as well as cell-dependent changes. 
In addition, monitoring needs to be adapted to the tem-
poral profile characterized by different influences and 
requirements.
Treatment of Secondary Injury and Deterioration
In principal, dictated by the progressive nature of evolv-
ing structural and functional deterioration our duty is to 
find ways and means to attenuate (= realistic goal) or 
even stop (= ideal situation) this development without 
endangering the patient. What is oversimplified by the 
dichotomy of e.g., ICP- versus CPP-targeted therapy is, 
in reality, much more complex. In fact, we might have to 
combine the AANS guidelines and the treatment strate-
gies advocated by Grände et al. known as the “Lund 
concept” [42] in the same patient at different time 
points. The following part summarizes new knowledge 
and novel developments for the different treatment 
steps considered essential in the treatment of intracra-
nial hypertension.
CPP- or ICP-Targeted Therapy – the All-Time 
Controversial Expanded by the Volume-Targeted 
Therapy (“Lund Concept”)
Based on a multitude of publications using different 
methods to determine cerebral perfusion (PET, sXe-CT) 
posttraumatic brain ischemia strongly influences neuro-
logic outcome. Consequently, maintenance of adequate 
cerebral perfusion is essential to avoid additional cell 
damage possibly aggravating underlying injury. In this 
context, adequacy of perfusion is difficult to define as it 
is subject to heterogeneous local and temporal changes 
with a strong interindividual variability [43], ranging 
from impaired perfusion [44] due to clotted or vasocon-
stricted or compressed vessels to increased perfusion 
(hyperemia) [43] caused by vasodilated or paralyzed 
vessels. If adequacy of perfusion is defined as sufficient 
metabolic support of neurons and glia, then metabo-
lism-related parameters in addition to cerebral perfu-
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Figure 5. Temporal profile of changes in maximum and mean ICP determined in 16 representa-
tive patients suffering from severe TBI. ICP was significantly increased on the first posttrau-
matic day and after 1 week, remaining elevated thereafter. Within 4 days, fentanyl and mid-
azolam were administered in their highest possible daily amount.
Under clinical conditions, infusion of fentanyl and midazolam followed the increases in ICP. 
Thus, it remains to be determined if a higher starting dose might attenuate subsequent intra-
cranial hypertension.
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sion must be continuously determined at bedside. This 
will allow us to respond to changes over time influenced 
by progression and resolution of hemorrhages and ede-
ma formation and also enable us to adequately react to 
iatrogenic manipulations and therapeutic interventions. 
Thus, aggressive therapeutic measures employed to in-
fluence cerebral perfusion without proper control might 
result in blood volume overload (hyperemia or flow-me-
tabolism uncoupling) under conditions of endogeneous-
ly or pharmacologically depressed metabolic demand 
[43]. This, in turn, could induce aggravating elevated 
ICP. The initial CPP value of 70 mmHg set as the thera-
peutic goal by the AANS in 2000 was recently ques-
tioned and revised by the AANS in 2003 based on the 
observed volume- and pressor-induced increase in inci-
dence of adult respiratory distress syndrome (ARDS) in 
patients who had been randomized to the CBF-targeted 
therapy [45]. As recently concluded by Juul et al., a CPP 
> 60 mmHg does not improve outcome providing ICP 
can be maintained < 20 mmHg [46]. Then again, others 
request to maintain CPP > 70 mmHg [47].
As clearly stated in the initial guideline, the AANS 
repeats that we are still faced with “insufficient data to 
support treatment standards” and suggests: “Cerebral 
perfusion pressure (CPP) should be maintained at a min-
imum of 60 mmHg. In the absence of cerebral ischemia, 
aggressive attempts to maintain CPP above 70 mmHg 
with fluids and pressors should be avoided because of the 
risk of adult respiratory distress syndrome.” The crucial 
detail in guiding adequate cerebral perfusion is exten-
sive monitoring. For this, we need to combine different 
approaches simultaneously, including focal and global 
assessment of metabolism and perfusion.
Contrary to the initial perception of a static ICP-CPP 
relationship, novel data show that the spatial and tem-
poral heterogeneity in impaired perfusion, disturbed 
metabolism, and metabolism-flow mismatch reflect a 
more dynamic relationship which appears to be differ-
ent for various lesions and could change over time with-
in the same patient. Consequently, the optimal thresh-
olds for ICP as well as CPP might not be isolated 
setpoints but could require more iatrogenic flexibility to 
adapt and guide therapeutic interventions by monitor-
ing cerebral metabolism, allowing higher ICP values 
(> 20 mmHg) as long as an adequate perfusion thresh-
old is maintained [48, 49]. Based on the calculated dy-
namic threshold levels for CPP and ICP, Chambers et 
al. could show that determined minimal CPP and maxi-
mal ICP values differ depending on extent/severity of 
underlying lesions [5]. Interestingly, minimum required 
CPP values were highest in patients with nonevacuated 
mass lesions (94 mmHg), possibly related to the con-
comitant compression of the microcirculation, requiring 
an increase in pressure gradient. An increase in CPP 
from approximately 70 to 90 mmHg appears necessary 
to reduce the ischemic brain volume, improve flow-me-
tabolism coupling, decrease oxygen consumption, and 
increase ptiO2 [50, 51].
As suggested by Cremer et al. in a small series of 
patients, daily pharmacological manipulations of CPP 
are suggested to determine the dynamic changes in CPP 
requirements [52]. Unfortunately, this small series of 
patients was heterogeneous in terms of underlying inju-
ries and concomitant therapeutic interventions.
Present conclusions. Despite the beneficial effects 
reported upon rigid dichotomy of CPP- versus ICP-tar-
geted therapy, the dynamic pathologic processes with 
their strong temporal and lesion dependency might re-
quire a more flexible approach allowing a combination 
of the CPP- versus ICP-targeted treatment strategies.
Hyperventilation
Initially envisioned as an elegant way to control ICP by 
simply increasing ventilation frequency or tidal volumes 
in mechanically ventilated patients, the therapeutic hy-
perventilation has been subject to controversial dis-
cussions, as hypocapnia can induce adverse effects and 
contribute to a worse outcome. In this context, vasocon-
striction with ensuing or impending ischemia as evi-
denced by decreases in cerebral perfusion [21, 53], re-
duced ptiO2 and SjvO2 values [25], and increased 
extracellular glutamate and lactate concentrations [53] 
have been reported. As shown by Carmona Suazo et al., 
daily short hyperventilation trials of 15 min reveal an 
increasing risk for hyperventilation-induced compro-
mise of cerebral oxygenation during the first 5 days as 
reflected by an elevated ptiO2/paCO2 reactivity ratio 
[54]. As suggested by Coles et al., threshold value of 
paCO2 ranges from 34 to 38 mmHg (= 4.5–5.0 kPa), im-
plying that even small changes in paCO2 during nor-
moventilation with normocapnic values can induce un-
favorable alterations [21]. Other groups, however, did 
not report any adverse effects and highlight a consistent 
decrease in ICP [55]. Brief episodes of hyperventilation 
which reduced posttraumatic cerebral perfusion were 
not associated with energy failure, even in regions where 
ischemic perfusion values were reached. Thus, Diringer 
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et al. concluded that underlying suppressed metabolism 
protects from hyperventilation-induced impaired per-
fusion [56].
Due to extensive experience gained within the past 
20 years, the official AANS guidelines suggest that 
chronic hyperventilation should definitely not be per-
formed during the first 5 days following TBI. In particu-
lar, hyperventilation should definitely be avoided within 
the first 24 h, as this time period is characterized by im-
paired cerebral perfusion and disturbed metabolic and 
energetic homeostasis. Hyperventilation decreases the 
already impaired perfusion even further, limiting nutri-
tional supply and oxygenation to damaged tissue, and 
may also induce lesion growth by disturbing cerebral va-
soreactivity and autoregulation. This may be of utmost 
importance in patients with more severe injuries as e.g., 
SDH and multiple contusions in whom vascular respon-
siveness to CO2 is reduced [57, 58]. In addition, hypo-
capnia can also impair cardiac, pulmonary and cardio-
vascular function [59].
Present conclusions. As concluded by a Cochrane 
review, randomized controlled trials are required to as-
sess the effectiveness of hyperventilation [60]. Hyper-
ventilation might only be an option if detailed assess-
ment of individual perfusion and metabolism pattern is 
available. Specific bedside monitoring is definitely in-
dispensable, since even small changes in paCO2 within 
its normal range can already induce adverse effects.
Osmotherapy: Mannitol and Small-Volume 
Resuscitation
Shifting of electrolytes and changes in osmotic gradients 
across the blood-brain barrier contribute to brain ede-
ma and brain swelling. Thus, manipulation of this os-
motic gradient appears to be a feasible therapeutic ap-
proach. In this context, mannitol and hypertonic saline 
solution with and without dextran have been investi-
gated under clinical conditions. Despite extensive expe-
rience with mannitol it still lacks evidence of efficacy, as 
concluded by a recent Cochrane review [61]. Mannitol 
with its strong osmotic potential expands plasma, there-
by reducing the hematocrit and blood viscosity, and in-
creases CBF and oxygen delivery within several minutes 
following its administration. These effects are predomi-
nant in patients with CPP values < 70 mmHg and re-
duced serum osmolarity [62]. Ultra-early administration 
of high-dose mannitol (1.4 g/kg) in the emergency room 
appears superior to low-dose mannitol (0.7 g/kg) to re-
verse clinical signs of impending brain death and im-
prove long-term neurologic outcome, as studied in se-
verely injured patients with a Glasgow Coma Scale score 
of 3 and bilateral abnormal pupillary widening [63]. 
Continuous infusion should be avoided, as mannitol 
may damage the blood-brain barrier or accumulate 
within the extracellular space which, in turn, could raise 
brain osmolality, thereby exacerbating ICP and increas-
ing brain swelling.
An alternative to mannitol are hypertonic solutions, 
referred to as small-volume resuscitation, as a small 
dose, usually 4 ml/kg body weight (approximately 250 
ml) of 7.2–7.5% NaCl/colloid solution is infused in ap-
proximately 20 min. In addition to its primary resuscita-
tive potential from trauma and hypotensive shock, this 
approach might also gain access to perioperative and 
intensive care treatment of patients with elevated ICP 
as suggested by Kreimeier & Messmer [64]. The high 
tonicity and the fact that hypertonic saline does not pen-
etrate the blood-brain barrier makes it a promising os-
motherapeutic agent. The decrease in ICP is thought to 
result from reduced water content in noninjured brain 
areas and the cerebellum without significantly changing 
global cerebral perfusion [65]. The transient reduction 
in ICP might be prolonged by continuous infusion but 
requires careful control to avoid adverse effects as e.g., 
electrolyte abnormalities, cardiac failure, bleeding dia-
thesis, phlebitis, central pontine myelinolysis, and re-
bound intracranial hypertension following uncontrolled 
infusion.
As recently published, administration of hyperton-
ic saline solution results in superior effects compared 
to mannitol by decreasing daily episodes of intracra-
nial hypertension with a reduced rate in therapy-re-
fractory increases in ICP [66]. However, morbidity and 
mortality were similar in both groups and the differ-
ence in osmotic strength (350 mOsmol/dose vs. 175 
mOsmol/dose) limits the power of this study. As sug-
gested by Horn et al., hypertonic saline solution might 
be an effective measure to decrease ICP which is oth-
erwise refractory to standard therapeutic approaches, 
i.e., mannitol and barbiturates [67]. When adminis-
tered during the prehospital phase, hypertonic saline 
solution did not result in improved mortality or mor-
bidity, as seen in a double-blind, randomized con-
trolled trial enrolling 229 comatose and hypotensive 
TBI patients [68].
In a recently published pilot study, equimolar doses 
of hypertonic saline and dextran solution (HSD, Res-
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cueflow) were compared to 20% mannitol solution. 
HSD caused a significantly greater decrease in ICP than 
mannitol and had a longer duration of effect than man-
nitol [69].
Present conclusions. As concluded in two recently 
published Cochrane database reviews, further detailed 
prospective, randomized, and blinded large-scale clini-
cal studies are required to determine if the wide confi-
dence intervals observed in the present investigations 
will reveal if hypertonic solutions are of significant im-
portance [70] and if mannitol is indicated to manage in-
tracranial hypertension in patients without an operable 
intracranial hematoma [61]. In this context, this treat-
ment modality needs to be investigated before admis-
sion, at various time points following admission to the 
hospital in dependence of underlying lesion, and in re-
gard to intracranial hypertension.
Choice of Volume to Increase CPP
To date, it is well accepted that volume infusion to cor-
rect hemodynamic stability should precede administra-
tion of vasopressors. However, the type and amount of 
fluids are still under debate. As recently shown, normo-
volemia with a fluid balance ranging from –594 to 4,859 
ml was associated with the least incidence of poor out-
come in hypothermic as well as normothermic patients 
compared to patients with lower or higher fluid balance 
[47]. Unfortunately, data of volume balance in patients 
treated according to the “Lund concept” are not avail-
able which might allow to more efficiently define re-
quired normovolemia in patients with severe TBI. Due 
to its plasma-expanding effects, colloid solutions are su-
perior to crystalloid solutions which need to be adminis-
tered in higher amounts to induce similar hemodynamic 
stability. As recently published, high amounts of hy-
droxyethyl starch administered repeatedly in severe 
TBI patients are safe [71]. As reported by the Saline 
versus Albumin Evaluation study, 4% albumin was not 
associated with an overall benefit compared to saline. 
However, patients with severe TBI within the albu-
min-treated group revealed a trend toward increased 
mortality [72].
Present conclusions. The ideal fluid balance remains 
to be determined in patients suffering from severe TBI. 
Providing a lower CPP can be adequately controlled 
and justified by specific monitoring, a timely reduction 
in volume administration might attenuate side effects, 
as e.g., ARDS known to increase morbidity in these pa-
tients.
Barbiturate Coma
Barbiturates can decrease elevated ICP in patients pre-
senting with otherwise therapy-refractory intracranial 
hypertension by reducing cerebral metabolism and oxy-
gen consumption, thereby decreasing vascular tone, in-
hibiting excitatory input and energetic impairment. 
However, adverse systemic side effects which can lead 
to serious complications related to hemodynamic insta-
bility and infections due to impaired immunocompe-
tence limit the administration to most extreme situa-
tions. The fact that patients can suffer from further 
episodes of increased ICP despite complete suppression 
of neuronal activity as evidenced by continuous EEG 
recording and an initial responsiveness, suggests that 
barbiturate coma might not be the ultimate step in our 
therapeutic hierarchy but might require additional spe-
cific treatment approaches. In this context, we must 
comprehend that EEG monitoring employed to guide 
barbiturate administration will only reflect changes in 
cortical neuronal activity. Alterations occurring in deep 
structures or involving astrocytes which encompass 
nearly 75% of the brain remain disguised. As observed 
under experimental conditions, barbiturates dose-de-
pendently decrease astrocytic clearance of glutamate 
[73], possibly resulting in additional functional and 
structural cell damage, as glutamate cannot be used to 
fuel intracellular energetic processes or aid in synthesiz-
ing the antioxidant glutathione. Under clinical condi-
tions, this, in turn, could result in increased energetic 
impairment as reflected by sustained cerebral oxygen 
extraction, progressing edema formation, and further 
increase in ICP. This increase in ICP during barbiturate 
coma could also stem from hyperemia, if CPP is not ad-
justed to the lowered metabolic demand during barbitu-
rate coma. The statement published within the official 
AANS guidelines that prophylactic administration of 
barbiturates is not indicated following severe TBI is 
questioned by the “Lund concept” and the fact that 
many features within the overall intensive care treat-
ment of these patients have changed due to extensive 
pathophysiological characterization of the different fea-
tures of TBI and development of specific treatment op-
tions. Controlling energetic impairment and deteriora-
tion by suppressing cerebral metabolism through 
co-infusion of low-dose thiopental could prevent pro-
gression of structural and functional cell damage and 
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reduce the risk of CPP-dependent increases in cerebral 
blood volume, as a lower CPP can be tolerated [74]. This 
hypothesis needs to be prospectively investigated at dif-
ferent centers.
Present conclusions. As concluded in a Cochrane 
database review published in 2000, barbiturate coma 
does not improve outcome in patients with severe TBI 
owing to its hypotensive effect [75]. Prophylactic barbi-
turate administration discouraged by the AANS, how-
ever, is challenged by the “Lund concept” and awaits 
detailed investigation. More detailed investigations us-
ing refined monitoring techniques and modern knowl-
edge are required to determine the benefit of initial 
low-dose barbiturate administration, at which ICP 
high-dose barbiturate coma is to be initiated, for how 
long barbiturate coma (low and high dose) needs to be 
maintained, and what level of neuronal suppression as 
determined by continuous EEG recording and meta-
bolic/neurochemical supervision is adequate.
Sedation and Analgesia
Following severe TBI, the injured brain is highly vulner-
able to any potentially adverse influence. In this con-
text, coughing and straining exert a certain mechanical 
stress due to an increase in ICP caused by decreased ve-
nous outflow [76]. This, in turn, carries the risk of caus-
ing additional hemorrhages and aggravating existing 
space-occupying lesions, thereby adding to the underly-
ing pathologic vicious circle of compression and edema 
formation. In addition, a concomitant increase in oxy-
gen consumption reflected by decreased SjvO2 in face of 
reduced CPP may occur during coughing while endotra-
cheal suctioning inadequately sedated TBI patients 
[76].
Sustained cellular activity is an energetically com-
promising condition of stress which adds to a depletion 
of energetic reserves, thereby reducing the threshold for 
additional, otherwise tolerable compromising events. 
To date, neurons with their different excitatory and in-
hibitory circuit receptors remain the primary direct 
pharmacological target although astrocytes account for 
a large portion of energy-consuming and -producing ef-
fects, owing to their plethora of different functions with-
in the neuronal-glial-endothelial syncytium [77].
A common manner to counteract these stress-relat-
ed changes and thus prevent additional injury is to in-
duce and maintain adequate analgesia and sedation. As 
outlined by Citerio & Cormio [78], many pharmacologi-
cal agents with characteristic differences in their phar-
macokinetic and pharmacodynamic profile are avail-
able to specifically control ICP and cerebral metabolism 
and reduce seizure activity in addition to the more gen-
eral aims of controlling pain, anxiety, and agitation, lim-
iting the stress response, facilitating care, and managing 
ventilatory support. For brain-injured patients it is im-
portant to maintain adequate supply with nutrients and 
oxygen to guarantee sufficient energy production. Be-
sides increasing oxygen delivery by optimized hemody-
namics, ventilation, and oxygen carriers, oxygen con-
sumption and demand are reduced by decreasing 
cerebral metabolism. Providing an intact metabo-
lism-flow coupling, a reduction in cerebral metabolism 
will decrease CBF, thereby reducing cerebral blood vol-
ume and ICP. In this context, it is important to remem-
ber that metabolism is suppressed dose-dependently 
until the EEG becomes isoelectric. Thereafter, minimal 
basal energy consumption cannot be suppressed any 
further. Thus, reduction of intracranial blood volume is 
also restricted.
In general, benzodiazepines (e.g., midazolam, lo-
razepam) or propofol are combined with opioids (e.g., 
morphine, fentanyl). As recently shown, disturbances in 
metabolism and metabolic suppression reactivity quan-
tified by transient propofol-induced burst suppression 
pattern are heterogeneous and influenced by underly-
ing brain lesions [79].
On a cellular level opioids activate specific µ-, δ-, κ-, 
and σ-receptors, of which µ-receptors mediate analgesia 
by inhibiting presynaptic release of excitatory transmit-
ters via decreased availability of calcium and stabilizing 
postsynaptic membranes by increasing permeability for 
potassium. While activation of µ-receptors reduces lib-
eration of norepinephrine and substance P, δ-receptors 
attenuate release of acetylcholine, and κ-receptors de-
crease liberation of dopamine.
Benzodiazepines require the endogenous inhibitory 
transmitter GABA (γ-aminobutyric acid) to increase 
the opening time of the chloride channel by allosteric 
modulation of the GABAA receptor. This results in a 
stabilization of pre- and postsynaptic membranes, by 
which excitatory inputs are blunted.
Propofol has several targets, as it directly activates 
GABAA receptors, inhibits the NMDA (N-meth-
yl-D-aspartate) receptor and modulates calcium influx 
through slow calcium ion channels [80].
Overall, the choice of agent, dosage, and duration of 
administration show a strong variability between coun-
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tries and hospitals which might have contributed to the 
failure of various pharmacological trials aimed at modu-
lating/inhibiting transmitter-mediated influences [81]. 
Some favor propofol to treat intracranial hypertension, 
as it dose-dependently reduces EEG activity. Others 
prefer benzodiazepines despite their “ceiling effect” in 
reducing cerebral metabolism and blood flow in fear of 
propofol-induced increase in hemodynamic instability, 
lipid load, and the potentially fatal “propofol infusion 
syndrome” characterized by severe metabolic acidosis, 
cardiac and peripheral muscle damage (necrosis), and 
circulatory collapse. This syndrome can be provoked by 
elevated catecholamine, glucocorticoid and cytokine 
levels [82] encountered in patients with severe TBI and 
is thought to be related to disturbed structural and func-
tional integrity of mitochondria [80].
The beneficial effects of these drugs in terms of re-
ducing cerebral metabolism and oxygen consumption 
are confronted with certain side effects. The most com-
mon problem is receptor desensitization or downregu-
lation developing during chronic continuous adminis-
tration of opioids and benzodiazepines which accounts 
for the diminishing effectiveness of these drugs as evi-
denced by coughing, straining and eye opening despite 
continuously infusing these drugs at their maximally 
recommended dose. In clinical practice, dosage of opi-
oids and benzodiazepines is increased following changes 
in ICP (Figure 5), suggesting that starting with higher or 
submaximal dose or adding a more potent sedating 
agent as e.g., low-dose thiopental as advocated by the 
“Lund concept” [42] might prevent further cellular de-
terioration known to contribute to subsequent intracra-
nial hypertension. Contrary to benzodiazepines, barbi-
turates activate GABAA receptors independently of 
GABA (at high dosage). Since CSF glutamate and hy-
poxanthine concentrations remained unchanged and 
even showed a trend to elevated levels during continu-
ous administration of midazolam and fentanyl (Figure 
5) and since thiopental significantly reduced CSF gluta-
mate and hypoxanthine in patients who developed ther-
apy-refractory intracranial hypertension during admin-
istration of fentanyl and midazolam [15], a combination 
of these drugs might be a more promising approach in 
conveying neuroprotection.
A further complication is drug-induced reduction in 
bowel function leading to impaired transport and up-
take of nutrients which compromises nutritional supply 
of energetic compounds. In addition, disturbed bowel 
function may even progress to paralytic ileus. Serious 
constipation might add to intracranial hypertension by 
elevating intraabdominal pressure known to reduce ce-
rebral venous outflow. Furthermore, prolonged admin-
istration of opioids may suppress pituitary function, 
thereby disturbing the hypothalamic-pituitary-adrenal 
axis, causing hormonal dysregulation, and suppression 
of the immune system [83].
While inducing and maintaining sedation in patients 
with severe TBI is a rather straightforward approach, 
the awakening phase might be underestimated in its 
pathophysiological importance. In this context, continu-
ous administration of opioids and benzodiazepines in-
duces tolerance and dependency due to altered receptor 
function and expression. Clinically, patients are ex-
tremely stressed upon reduction or discontinuation of 
drugs. The observed psychovegetative dysregulation re-
sulting in hyperdynamic circulation, fever, and physical 
agitation might again endanger cerebral viability. Usu-
ally, neuromonitoring has already been discontinued, 
leaving us without any data for this serious phase. In 
general, administration of the α2-adrenergic agonist 
clonidine is used to attenuate these alterations.
Present conclusions. To date, choice, dosage, and 
length of administered analgetics and sedatives are at 
the discretion of individual centers. A standardized pro-
tocol might improve comparability of patients in multi-
center studies. Since level of sedation assessed by EEG 
activity is judged as incomplete upon administration of 
benzodiazepines, specific receptor modulation might 
regain importance when aiming at metabolic stability to 
reduce intracranial hypertension and increase survival 
rate rather than anticipating complete restoration of 
higher cognitive functions. More detailed investigations 
are required to determine potential adverse effects dur-
ing the arousal phase overshadowed by withdrawal 
symptoms which might destroy previous successful pro-
tection.
Fever, Therapeutic Hypothermia, and Temperature 
Control
Based on experimental and clinical data, increases in 
rectal temperature > 38.5 °C corresponding to brain 
temperature levels of 40–41 °C are associated with ad-
verse biochemical alterations leading to functional and 
structural deterioration, resulting in increased posttrau-
matic morbidity and mortality [84]. Consequently, con-
trolled normothermia of body and brain as well as pre-
vention of fever are considered important basic 
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treatment modalities in modern therapy of patients with 
severe TBI [84]. The next logical step was to induce hy-
pothermia by which reduced cerebral metabolism might 
convey protective effects. However, therapeutic hypo-
thermia following severe TBI could not reproduce the 
beneficial effects observed in patients with cardiac ar-
rest who had been cooled to 32–33 °C for 24 h [85]. In a 
recently published carefully conducted clinical study, 
Tokutomi et al. [86] concluded that maintaining rectal 
temperature between 35 and 35.5 °C results in an opti-
mal relationship between decreased ICP, metabolic 
suppression, adequate cerebral perfusion, and least sys-
temic side effects known to offset anticipated protection 
once body temperature drops to < 35 °C [87].
As observed with the administration of sedatives and 
analgetics, induction and maintenance of hypothermia 
and rewarming are at the discretion of different centers 
and reveal strong variations [88]. In this context, begin-
ning, degree and length of hypothermia, means to induce 
hypothermia, and speed of rewarming need to be rede-
fined. Some favor normothermia (37–38 °C) which, how-
ever, is associated with elevated ICP [86], while others 
maintain body temperature between 35 and 37 °C. Other 
groups will only initiate deep hypothermia (32–34 °C) in 
patients requiring barbiturate coma due to refractory in-
tracranial hypertension [89]. Rewarming ranges from 
1 °C/d to 1 °C/h [88]. Furthermore, the technique of mea-
suring temperature shows a strong variability between 
centers. In this context, brain temperature is accepted to 
exceed body core temperature determined in the jugular 
bulb, pulmonary artery, esophagus, tympanic membrane, 
and bladder by 2 °C, which means that we might be un-
derestimating intracerebral changes.
Fever or temperature control also differs strongly 
between institutions. While some centers propagate 
early administration of the antipyretic drugs acetamino-
phen and ibuprofen directly upon admission, other cen-
ters are more reluctant to give these antipyretic drugs to 
avoid possible adverse side effects in ICU patients.
The least expensive way to reduce body temperature 
is to use surface cooling blankets. However, this me -
thod results in episodes of difficult-to-control decreases 
and increases in body temperature, sometimes 
> 2 °C within a few hours. In addition, body temperature 
usually increases abruptly within a few hours to levels 
> 38 °C. In the meantime, more sophisticated techniques 
have been developed, ranging from hydrogel-coated wa-
ter-circulating energy transfer pads applied directly to 
the trunk and thighs [90] to special cooling helmets [91] 
and endovascular cooling employing heat exchange cath-
eters [92] which are superior in terms of controlling tem-
perature during hypothermia and rewarming.
Present conclusions. The need to prevent fever is 
unanimously accepted. However, therapeutic hypother-
mia remains a topic fueling controversial discussions. 
To date, degree of hypothermia, means and time point 
of inducing as well as maintaining hypothermia are at 
the discretion of individual centers, requiring a stan-
dardized protocol, also referring to use of antipyretic 
drugs. It remains to be determined if quantitative or 
qualitative changes in body temperature during main-
tained hypothermia are harmful, which speed of re-
warming is allowed without inducing additional injuries, 
and if neuromonitoring needs to be extended to the 
post-rewarming phase.
Elevated Intraabdominal Pressure
In recent years, clinical awareness concerning deleteri-
ous effects of intraabdominal hypertension on nearly all 
organ systems has prompted different means of treat-
ment, ranging from curarization to application of exter-
nal negative abdominal pressure and surgical decom-
pression [93] which have been shown to reduce ICP and 
decrease mortality [94]. Following TBI, abdominal hy-
pertension has been shown to elevate ICP and decrease 
CPP closely following the dynamics and kinetics of the 
intraabdominal pressure which is of high concern in pa-
tients presenting with already increased ICP [95].
Dysregulated bowel movements may also contrib-
ute to abdominal hypertension. In this context, our own 
investigations suggest that some patients might also 
profit from enemas, as elevated ICP was significantly 
decreased from 22 ± 9 to 13 ± 7 mmHg for a median 
duration of 4 h (1–23 h) in 38% of prospectively investi-
gated 67 patients with severe TBI. These results reveal 
that exploited intracranial compensatory mechanisms 
to counteract elevated ICP strongly depend on mea-
sures which can decrease pressure load transmitted 
from lower body cavities by improving cerebral venous 
outflow.
As recently shown, the composition of the enema 
used might also directly influence the cerebral compart-
ment as cerebral extracellular glycerol was significantly 
increased [96]. Whether the absorbed glycerol is able to 
equally reduce elevated ICP and improve CPP as ob-
served following intravenous infusion remains to be de-
termined.
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Present conclusions. Mechanistically, intraabdomi-
nal hypertension following fluid overload or dysregu-
lated bowel movements contributes to intracranial hy-
pertension. Prospective, randomized studies are needed 
to determine if prophylactic measures are required and 
which interventions need to follow a standardized pro-
tocol.
Steroids
Ever since its identification to inhibit the activity of 
phospholipase A2, thus preventing downstream gen-
eration of various destructive prostaglandins and leu-
kotrienes, steroids were praised for their antiedema-
tous potency. This beneficial action as documented for 
brain tumors, however, has been subject to controver-
sial discussions for TBI patients. As shown by the re-
cently published results of the international multi-
center, prospective, randomized, and double-blind 
study CRASH, this issue has finally been resolved. In 
this study, 10,008 patients with mild and severe TBI 
were randomized to receive methylprednisolone (load-
ing dose 2 g/first hour, followed by 0.4 g/h for the fol-
lowing 48 h) or placebo. With 5,007 patients in the 
verum and 5,001 in the placebo group, mortality was 
significantly increased during the initial 2 weeks fol-
lowing injury with a trend to a higher incidence in sei-
zure activity, gastrointestinal hemorrhages, wound in-
fections, and pneumonia in patients receiving the 
steroid [97]. Given the plethora of different side effects 
which are possibly potentiated by other drugs, as e.g., 
catecholamines and certain pathologic alterations 
which are characteristic of severely injured critical care 
patients, as e.g., peripheral insulin resistance, increased 
energy expenditure with hormonal, inflammatory, and 
immunologic dysfunction, steroids should no longer be 
considered for acute cerebral (and spinal) injuries. In 
this context, glucocorticoids inhibit the cellular and 
humoral immune response, decrease insulin respon-
siveness of muscle and fat tissue, increase blood glu-
cose levels, decrease muscle mass, may promote myo- 
and neuropathy, disturb plasma electrolytes via their 
mineralocorticoid effects, and can hamper the func-
tion of the hypothalamic-pituitary-adrenal axis which 
can already be disturbed by TBI itself. Under experi-
mental conditions, glucocorticoids have been shown to 
aggravate underlying brain damage by increasing met-
abolic vulnerability in neurons due to inhibition of glu-
cose uptake, exacerbating glutamate-induced excito-
toxicity, disrupting mobilization of neurotrophins, 
inhibiting the local inflammatory response [98], and 
reducing cerebral antioxidative capacity [99].
Present conclusions. Contrary to the hypothesized 
improved outcome following TBI, the large multicenter, 
placebo-controlled, double-blind study conducted by 
the MRC CRASH trial has negated its implementation 
within the standard treatment regimen of patients with 
severe TBI.
Hormonal Dysregulation
TBI is associated with structural and functional distur-
bances of the hypothalamic-pituitary-adrenal axis re-
sulting in diminished blood levels of various hormones 
originating from the anterior and posterior pituitary. 
These disturbances which depend on the severity of un-
derlying TBI [100] occur early after TBI [101] and have 
been shown to persist up to 5 years [100, 102, 103]. Due 
to prolonged persistence of these endocrinological al-
terations and the fact that these disorders contributing 
to morbidity following TBI are treatable, more detailed 
investigations to determine need and efficacy of correc-
tive treatment paradigms starting during the intensive 
care phase must be conducted [100, 102].
Structural disturbances can result from hemorrhag-
es and infarctions of the pituitary or hypothalamus as 
well as traumatic stalk resections. Functional distur-
bances can result from sustained or impaired feedback 
inhibition or continuous activation by routinely admin-
istered drugs (e.g., opioids, catecholamines). In this 
context, exogenously administered dopamine can in-
duce hypopituitarism reflected by suppression of circu-
lating concentrations of all anterior pituitary-dependent 
hormones [104] and noradrenaline might contribute to 
the observed adrenal insufficiency [105]. Disturbances 
of the anterior and posterior pituitary can result in sig-
nificant changes in blood electrolyte levels which, in 
turn, can induce edema formation and aggravate preex-
isting edema due concomitant osmotic shifts (hypo- and 
hypernatremia), upregulation of glial aquaporin (hypo-
natremia), and changes in volume-regulatory osmolytes 
(taurine, glutamate, aspartate, glutamine) leading to 
sustained intracellular water accumulation. Blunted or 
sustained release of the antidiuretic hormone (ADH) 
from the posterior pituitary gland results in increased 
and decreased plasma sodium levels, respectively. Apart 
from TBI-induced alterations, barbiturates and opioids 
are also known to stimulate release of ADH. Sustained 
TBI-induced stimulation of the anterior pituitary gland 
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results in elevated liberation of adrenocorticotropic 
hormone (ACTH) which increases release of cortisol 
and aldosterone from the adrenal gland. Hyperaldoste-
ronemia results in hyponatremia. Diminished produc-
tion of aldosterone due to blunted stimulation of the 
adrenal gland caused e.g., by hypothalamic or pituitary 
damage with subsequent diminished release of ACTH 
or irresponsiveness of the adrenal gland to ACTH due 
to receptor downregulation following prolonged stimu-
lation can result in hyponatremia, hyperkalemia, hyper-
magnesemia, and acidosis. This, in turn, can result in 
hypotonic dehydration and disturbed vascular autoregu-
lation via developing acidosis. Hypoaldosteronemia can 
also result from opioid administration or sustained nega-
tive feedback via elevated circulating cortisol levels.
On a cellular level, various mechanisms have been 
identified to contribute to edema development follow-
ing dysnatremia. In this context, osmoregulatory osmo-
lytes and water transport channels are highlighted. Un-
der conditions of hypertonic stress as seen with 
hypernatremia, the first cellular response is to shrink as 
water leaves the cell until a new balance between intra- 
and extracellular osmolality has been reached. Thereaf-
ter, uptake of electrolytes with increased intracellular 
osmolality and water uptake restores original cell vol-
ume. This fast response is mainly observed during tran-
sient (acute) hypertonic stress and is associated with an 
activation of various energy-consuming electrolyte 
transporter proteins [106]. However, this pathologically 
increased intracellular ionic burden can impair function-
al and structural integrity of these cells. Under condi-
tions of prolonged hypertonic stress which is clinically 
relevant when hypernatremia persists > 24 h, secondary 
adaptation process, i.e., energy-dependent accumulation 
of organic osmolytes is then initiated in exchange for 
electrolytes. The energy dependency of these adaptive 
mechanisms in face of underlying compromised metabo-
lism and disturbed cellular functionality might not result 
in normalized cell volume but persisting cellular edema. 
If hypernatremia is corrected too rapidly (> 0.5 mmol/l/
h), water will be driven into the cerebral extracellular 
space, resulting in sustained cellular edema formation, 
as neurons and astrocytes had previously accumulated 
organic osmolytes. Restoration of normal intracellular 
composition is accepted to last for at least 5–7 days. In 
case of hypotonic stress, i.e., hyponatremia, the initial 
response in cellular swelling is followed by a subsequent 
release of various organic osmolytes as an unspecific re-
sponse of cells to reinstate a balanced intra- and extra-
cellular osmolality [107]. The magnitude of this response 
depends on the speed at which hyponatremia develops. 
The release of osmolytes, especially glutamate and as-
partate known for their excitotoxic potential, might 
damage the already injured brain tissue following TBI 
even further. If this hyponatremia is corrected too fast, a 
relative and absolute hypernatremia can then induce 
pathologic alterations as outlined above.
From our own experience, patients can go through 
phases dominated by isolated hypo- and hypernatremia 
or sequential changes with preceding or following hypo- 
and hypernatremia, respectively. These phases appear 
to be self-limited, as no specific, i.e., hormonal correc-
tion was performed. In a series of 40 consecutively in-
vestigated patients with severe TBI, 13% developed 
hyponatremia and 28% presented with hypernatremia. 
ICP was lowest in patients with plasma sodium concen-
trations ranging from 120 to 129 mmol/l (16 ± 1 mmHg) 
and remained at 18 ± 1 mmHg when plasma sodium lev-
els ranged from 130 to 155 mmol/l. However, plasma 
sodium levels > 155 mmol/l were associated with signifi-
cantly increased ICP values (24 ± 1 mmHg). Plasma so-
dium > 165 mmol/l was associated with death due to 
therapy-refractory intracranial hypertension.
As pointed out in various reviews, it is essential to 
slowly correct the dysnatremias to avoid worsening or 
induction of neurologic damage. Apart from symptom-
atic therapies by slowly infusing NaCl or restricting vol-
ume administration – which might be difficult in hemo-
dynamically unstable patients or those requiring volume 
to maintain adequate CPP – pharmacological interven-
tions using oral vasopressin receptor antagonists [108] 
or low-dose aldosterone antagonists to correct hypona-
tremia and hypernatremia, respectively, might be valu-
able alternatives.
Since any cell is capable of regulating its volume 
through shifting of water, electrolytes and volume-regu-
latory osmolytes (e.g., glutamate, taurine) [109], we 
might be able to use isolated erythrocytes to determine 
the effects of hyper- and hyponatremia, and to also 
guide the speed of correction allowing to adapt specific 
or symptomatic therapeutic interventions accordingly. 
Since these critically ill patients might also depict other 
hormonal disturbances [105] suppressing the adrenal 
responsiveness to corticotropin-releasing hormone 
(CRH) and release of cortisol, replacement therapy 
with low-dose hydrocortisone with its mineralocorticoid 
effects might be considered an option in these patients 
presenting with hyponatremia.
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Present conclusions. Following severe TBI, hor-
monal disturbances can induce dysnatremias which, in 
turn, can contribute to intracranial hypertension. Rou-
tinely, specific diagnostic tests are only performed when 
dysnatremias are present. Maybe daily analysis might 
aid in detecting ensuing changes. To date, only symp-
tomatic approaches are available to slowly correct dys-
natremias. This, however, is associated with the risk of 
strong variations. It remains to be determined if phar-
macological interventions might result in a superior 
controlled correction. Given the volume-regulatory re-
sponse encountered in any cell, erythrocytes might be 
used to control correction of dysnatremias by measur-
ing the release of volume-regulatory osmolytes as e.g., 
glutamate and taurine in addition to assessing changes 
in cell volume.
Nutrition: Possible Consequences on Intracranial 
Pathology
Hormonal dysregulation observed in any critically ill 
patient is more sustained in patients with severe TBI as 
judged by the increased energy expenditure [110]. To 
counteract the ensuing catabolism, various enteral and 
parenteral nutrition solutions have been developed to 
ameliorate weight loss, negative nitrogen balance, im-
mune dysfunction, increased infection rate, thereby im-
proving morbidity and mortality. However, some of the 
amino acid components, i.e., glutamate and arginine, 
might exert a negative impact on the already compro-
mised intracranial compartment. In this context, gluta-
mate might penetrate the cerebral extracellular space 
and possibly contribute to cytotoxic edema formation 
owing to its excitotoxic potential. Arginine, the physio-
logical precursor of the vasodilating nitric oxide (NO), 
could induce intracranial hypertension. Infusing a com-
mercially available glutamate-containing amino acid 
solution doubled plasma glutamate levels within 2 h 
compared to a glutamate-free solution [111]. Intrave-
nous infusion of a glutamate- and arginine-enriched 
amino acid solution significantly elevated correspond-
ing plasma levels [112]. Interestingly, repetitive infu-
sions were associated with a progressive increase in 
plasma levels over time. To date, it is unclear if the po-
tential pathophysiological importance of these altera-
tions might detract from the beneficial effects in terms 
of significant decrease in skeletal muscle myofibrillar 
catabolism and positive nitrogen balance.
Glutamine is a semi-essential amino acid which be-
comes indispensable under pathologic conditions. Its 
supplementation has been reported to enhance cellular 
immunologic functions, increase survival, and attenuate 
muscle catabolism and intestinal dysfunction [113]. Sub-
sequent metabolism of enterally or parenterally admin-
istered glutamine to glutamate and arginine is feared, as 
these amino acids could induce or aggravate underlying 
injury mediated by excitotoxicity and vasodilation, re-
spectively. In this context, enteral glutamine infusion 
via a double-lumen nasojejunal tube significantly and 
dose-dependently increased plasma glutamate concen-
trations [114]. To date, the glutamine-driven increase in 
jugular venous glutamate as reported by Petersen et al. 
in 1996 [115] has neither been confirmed nor disputed. 
To date, it remains unclear whether enteral or paren-
teral supplementation with low-dose glutamine with its 
immunosupportive potential increases arterial plasma 
glutamate levels, thereby potentially endangering the 
already injured brain.
A mismatch between aromatic amino acids (me-
thionine, phenylalanine, tryptophane, tyrosine) and 
branched-chain amino acids (leucine, isoleucine, va-
line) within the group of neutral amino acids contrib-
utes to metabolic encephalopathy, as these amino ac-
ids compete for the same transporter located at the 
blood-brain barrier. A relative increase in aromatic 
amino acids displaces the branched-chain amino acids, 
thereby impairing detoxification of produced NH4
+ 
and promoting sustained production of excitatory 
transmitters (dopamine, norepinephrine, serotonin) 
and synthesis of false neurotransmitters (tyramine, 
phenylethanolamine, tryptamine). A relative increase 
in branched-chain amino acids, in turn, decreases the 
availability of catecholamine precursors which could 
produce biochemical and neuropsychological changes 
consistent with impaired dopamine neurotransmission 
[116]. Taken together, these alterations could aggra-
vate underlying damage which might require more 
specific pharmacological intervention or adaptation of 
the nutrition.
Present conclusions. Nutritional support is essen-
tial in attenuating evolving catabolism. Whether ingre-
dients of enteral and parenteral solutions might com-
promise intracerebal pathology even further by e.g., 
elevating plasma glutamate and arginine concentra-
tions or increasing a mismatch between aromatic and 
branched-chain amino acids requires further detailed 
investigations. The time point at which administration 
of glutamine following severe TBI may be adequate to 
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support immunologic competence remains to be deter-
mined.
Hyperglycemia
Overall, both low and high blood glucose levels can ag-
gravate underlying brain damage, increase edema for-
mation, thereby contributing to intracranial hyperten-
sion.
A large body of evidence underscores the adverse 
effects of increased blood glucose levels following se-
vere TBI, implementing that prevention of hyperglyce-
mia will aid in preventing brain tissue acidosis [117] and 
avoiding worsened ouctome [118]. On a cellular level 
within the central nervous system, sustained hypergly-
cemia results in an accelerated uptake and subsequent 
metabolism of glia and neurons known to be overly ac-
tive following TBI, especially within pericontusional 
areas [119]. This, in turn, might increase lactate produc-
tion, if oxidative degradation of glucose is hampered 
due to impaired mitochondrial function and compro-
mised citric acid cycle, thus fueling ATP (adenosine tri-
phosphate) production via the alternative pathway 
when pyruvate is transformed to lactate via lactate de-
hydrogenase (LHD). Production of lactate decreases 
brain tissue pH which may deactivate various enzymes, 
activate destructive intracellular cascades and ener-
gy-consuming pumps, thereby impairing functional and 
structural integrity of the brain in face of its limited en-
ergetic reserves even further. As suggested by the re-
cently published results by the group of Christian Nord-
ström only hyperglycemic values > 15 mmol/l are 
associated with a moderate increase in interstitial lac-
tate levels [120].
In the critically ill, accelerated glucose toxicity is 
attributed to a cellular glucose overload in organs and 
cells known for their insulin-independent glucose up-
take involving not only the central and peripheral 
nervous system, but also hepatocytes, endothelial, epi-
thelial, and immune cells. Sustained oxidative phos-
phorylation can result in peroxynitrite generation 
which, in turn, damages mitochondria and impairs var-
ious intracellular enzymes [121]. Furthermore, hyper-
glycemia can induce functional incapacitation of the cel-
lular and humoral inflammatory/immune response. The 
concept of maintaining blood glucose at low levels with-
in tight limits (80–110 mg/dl = 4.4–6.1 mmol/l) reported 
to reduce mortality and morbidity in any patient with 
chronic and acute nondiabetic disease requiring inten-
sive care treatment [122] has also been propagated to be 
beneficial following severe TBI. However, the actual 
data for this subpopulation has not been described in 
detail to date.
Glucose uptake strongly depends on the involved 
glucose transporters with their differentiated function-
ality and regulatory features, and their characteristic 
distribution between and within different organs. With-
in the central nervous system virtually all glucose trans-
porters (GLUT) are expressed [123]. GLUT1 is mainly 
found on astrocytes and endothelial cells, GLUT2 is lo-
calized on astrocytes, and GLUT3 is predominantly ex-
pressed by neurons. The amount of expressed high-af-
finity GLUT1 and GLUT3 strongly influences the rate 
of glucose uptake. An upregulated expression of these 
glucose transporters could mediate glucose toxicity at 
normal or even low glucose levels. By contrast, the rate 
of glucose uptake by the low-affinity GLUT2 increases 
in parallel with the rise in blood glucose, thus markedly 
endangering GLUT2-carrying cells, i.e., astrocytes, 
through glucose-mediated cell damage. Conversely, a 
decrease in blood glucose could result in reduced cere-
bral uptake. Glucose uptake can be controlled by down- 
or upregulation of expressed transporter proteins [124]. 
In this context, hyperglycemia downregulates GLUT1 
while chronic hypoglycemia upregulates GLUT1. In ad-
dition, hypoxia upregulates GLUT1 and GLUT3 to 
provide the cell with sufficient amounts of glucose in 
face of damaged mitochondria. As recently shown, glu-
cose transport determined by 18F-FDG (fluorine-18-la-
beled fluorodeoxyglucose) kinetic modeling was signifi-
cantly reduced within pericontusional cortex [119]. In 
addition to the described regional heterogeneity an in-
terindividual variability with an increased pericontu-
sional 18F-FDG uptake was observed in five of the 21 
studied patients.
Induction and maintenance of low blood glucose 
levels require administration of high doses of insulin es-
pecially during the early posttraumatic phase which is 
dominated by skeletal and hepatic insulin resistance 
and hormonal dysregulation. While van den Berghe et 
al. do not report hypoglycemic episodes [121], this pos-
sibility remains of utmost importance, since a decrease 
in blood glucose levels to < 4.9 mmol/l [125, 126] in-
creases postischemic seizures and peri-infarct depolar-
izations known to further impair tissue viability and also 
increase mortality under experimental conditions. As 
just recently published, the regional and temporal het-
erogeneous disturbance in cerebral metabolism associ-
ated with low extracellular glucose concentrations was 
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associated with an increased rate of spreading-depres-
sion-like events in the perilesional cortex which might 
contribute to an increased mortality in TBI patients 
[127].
Retrospective analysis of 30 patients with severe 
TBI revealed that approximately 34% of 1,630 blood 
glucose values documented in 4-hourly intervals ex-
ceeded the upper limit of 6.1 mmol/l, reflecting that 
even continuous insulin administration fails to com-
pletely control blood glucose levels. Attributed to the 
administered insulin, we observed hypoglycemic values 
in approximately 8%. If we consider 5 mmol/l a more 
appropriate lower limit to prevent uncontrolled depo-
larizations [126], we would have then induced endan-
gering situations in approximately 22% of the 1,630 val-
ues.
Present conclusions. Fueled by recent clinical trials 
and experimental studies, the optimal limits for blood 
glucose levels need to be defined to assure least adverse 
effects for the already impaired energetic cerebral ho-
meostasis. Detailed clinical and experimental studies 
are required to determine which variations in blood glu-
cose are tolerable, at which speed these changes are al-
lowed to occur without inducing adverse side effects, 
and if there is a temporal dependency influenced not 
only by resolution of the catabolic postaggression phase 
but also by strong daily and circadian variations in ener-
getic supply.
Potential New Approaches
Improving oxygen delivery remains an area of interest 
which goes through phases of controversial popularity. 
In this context, experimental data suggest that resuscita-
tion with diaspirin cross-linked hemoglobin, a hemoglo-
bin-based oxygen carrier with pressor activity, might 
dose-dependently decrease ICP and increase CPP as 
observed in a combined model of TBI and hemorrhagic 
shock. However, the reduced cardiac performance 
might become limiting under clinical conditions [128].
Hyperbaric as well as normobaric hyperoxia have 
been reported to attenuate signs of impaired metabo-
lism and also improve outcome in patients with severe 
TBI [129, 130]. However, these approaches are over-
shadowed by certain limitations and by findings ruling 
out a beneficial effect based on microdialysis studies 
[131]. Hyperbaric oxygenation requires special cham-
bers with addditional technical, logistic, and academic 
support. Although normobaric hyperoxia is easy to per-
form, both interventions might induce vast tissue dam-
age via generated oxygen radicals, induced stress re-
sponse, activated pro-inflammatory cytokines, and 
initiated intracellular destructive cascades [132].
The majority of patients suffering from severe TBI 
present with systemic and/or intracranial hemorrhages 
which can progress to life-threatening coagulopathy re-
quiring specific and immediate therapeutic interven-
tions to prevent mortality and ensuing morbidity due to 
shock-related hypoperfusion, hypothermia, and acido-
sis, known as the “lethal triad” of irreversible shock. 
Recent introduction of the recombinant activated hu-
man coagulation factor VII (FVIIa) in the clinical ther-
apy of patients with traumatic coagulopathy might 
progress to a valuable routine treatment option for pa-
tients with severe TBI [133]. To date, administration of 
FVIIa is a therapy of last resort. Currently, a prospec-
tive multicenter study is under way to evaluate effects 
of routine application in patients with contusions > 5 
ml. Upon binding to tissue factor at the site of injury, 
FVIIa induces a “thrombin burst” on the surface of ac-
tivated platelets and thereby potentiates fibrin forma-
tion. The developing barrier against proteinase inhibi-
tors confines the clot to the site of injury and plugs the 
bleeding vessel. However, the induced “thrombin 
burst” might endanger cerebral viability via activation 
of specific neuronal and glial thrombin receptors. While 
low concentrations can protect neurons and astrocytes, 
high doses can become lethal, disrupt the blood-brain 
barrier and induce edema formation [134]. In a recently 
published experimental study, continuous infusion of 
thrombin stressed its neurotoxic potential and ensuing 
memory impairment [135]. Whether similar toxic 
thrombin concentrations are reached upon single-dose 
administration under clinical conditions remains to be 
determined to possibly assess and monitor adverse ef-
fects.
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